North Kingstown, RI - Unetixs Vascular Inc., an established and well-known global entity in the specialized vascular lab, is now in full production of the new Revo® 1100, a system to detect Peripheral Arterial Disease (PAD). The Revo 1100 is a standalone, automated system for PAD diagnosis that utilizes Doppler, dual channel calibrated PVR and PPG.

The portable Revo®, designed for general use in the doctor's office, incorporates technology found in lab based equipment yet it is configured, packaged and priced for the solo practitioner or group practice.

The Revo® establishes a patient's Ankle Brachial Index (ABI) quickly and accurately. The ABI is the baseline study to detect PAD, a malady that affects 12 million people in the United States alone. Revo® utilizes new composite technology in its TruDop® probe making it the most durable probe of its type on the market. Calibrated Pulse Volume Recording (C-PVRTM), a key element in diagnosis and reimbursement, and Photoplethysmography (PPG) for digit studies round out the diagnostic capabilities of Revo®.
"Cardiologists, primary care physicians and podiatrists will appreciate the speed and accuracy of Revo®," said Peter Moscovita, president and CEO of Unetixs. "The Revo® is entirely manufactured by Unetixs. Our quality standards are built into our sensors, cuffs, carts and accessories. Nothing, except the printer, is off-the-shelf."

Unetixs, a leader in serving the medical community, brings together advanced technologies and human resources to deliver instrumentation, education, and publication. Products offered supply accurate results and significant return on investment to customers through high-value innovative solutions. Unetixs assists clients in managing patient loads with agility and growth by transforming their infrastructure and processes to optimize existing assets, lower costs, and provide new revenue streams.

For more information, visit the Unetixs web site at www.unetixs.com.

More Voices